- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03610308
ESTES Snapshot Audit 2018
European Society for Trauma and Emergency Surgery (ESTES) Cohort Study Snapshot Audit 2018 - Acute Complicated Biliary Disease
Study Overview
Status
Detailed Description
Background: Acute complications of biliary calculi are common, morbid and complex to manage. Variability exists in the techniques utilised to treat these conditions at a surgeon and unit level. This high-quality pan-European prospective audit will establish current practices and correlate them against outcomes.
Aim: To explore differences in patients, techniques and outcomes across the international cohort to identify areas of practice variability in the presentation and management of acute complicated calculous biliary disease.
Endpoints: A two-stage data collection strategy collecting patient demographics, details of operative, endocopic and radiologic intervention and outcome metrics. Several outcomes measures will be used including mortality, surgical morbidity (including Clavien-Dindo Grade 3a and above), ICU stay and length of hospital stay.
Methods: This 30 day prospective audit will be performed across Europe in late autumn 2018, and will be co-ordinated by the Emergency Surgery Cohort Study committee of European Society of Trauma and Emergency Surgery. This will be preceded by a one-week, three-centre pilot. Sites will be asked to pre-register for the audit and will be required to obtain appropriate regional or national approvals in advance of the enrolment date. The ESTES cohort studies committee will assist sites to register where possible.
During the study period, all eligible patients with acute complicated biliary calculous disease will be recorded contemporaneously and followed-up through to 60 days from their admission. The audit will be performed using a standardised pre-determined protocol and a secure online database. The report of this audit will be prepared in accordance with guidelines set by the STROBE (strengthening the reporting of observational studies in epidemiology) statement for observational studies.
Discussion: This multicentre, pan-European audit of acute complicated biliary calculous disease will be delivered by emergency surgeons and trainees in an organised and homogenous manner. The data obtained about areas of variability in provision or practice, and how this may impact upon outcomes, will serve to improve overall patient care as well as being hypothesis generating and inform areas needing future prospective study.
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
-
Dublin, Ireland
- Tallaght University Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
- Pan-European, prospective audit of consecutive patients admitted for the treatment of complicated calculous biliary disease over a 30-day study period. The audit shall include unscheduled admissions from 1 October 2018 to 31 October 2018.
- Commencement timeframe: The sites will start within a time window from 1 October to 31 October 2018. Following commencement, the sites will be required to include all eligible consecutive patients for 30 consecutive days.
- Final date for operation inclusion: The sites can include admissions that occur up to 31 October 2018.
- All patients will be followed for 60 days post-admission. Data collection should therefore be completed by 31 December 2018.
- As this is an observational cohort audit, no change to normal patient management is required.
Description
Inclusion Criteria:
Adult patients (over 18 years of age) admitted for:
- Acute gangrenous or perforated calculous cholecystitis (AAST Severity Grade II or above)
- Choledocholithiasis or complications of cholelithiasis and/or choledocholithiasis
- Biliary Pancreatitis
Procedures which should be included:
- Cholecystectomy (open, laparoscopic or robotic)
- Choledochotomy/common bile duct exploration (open, laparoscopic or robotic)
- Pancreatic necrosectomy
- Gastrojejunostomy
- Cyst gastrostomy
- Endoscopic retrograde choledochopancreatography (ERCP) or Endoscopic ultrasound (EUS)
- Percutaneous cholecystostomy (transhepatic or transperitoneal)
- Percutaneous transhepatic drainage, stone removal or stent placement
Exclusion Criteria:
- Uncomplicated biliary colic
- Biliary dyskinesia
- Acute calculous cholecystitis (AAST Grade I)
Study Plan
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Mortality
Time Frame: 60 days
|
Overall and disease-related mortality
|
60 days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
ICU Admission
Time Frame: 60 days
|
Intensive Care Unit admission for organ-supportive therapy
|
60 days
|
Length of hospital stay
Time Frame: 60 days
|
Length of hospital stay
|
60 days
|
Complications
Time Frame: 60 days
|
Complication related to surgical, endoscopic or radiologic intervention
|
60 days
|
Collaborators and Investigators
Investigators
- Study Chair: Gary A Bass, MD, MSc, MBA, Tallaght University Hospital, Dublin, Ireland
- Principal Investigator: Shahin Mohseni, MD, PhD, Örebro University Hospital, Sweden
- Principal Investigator: Jorge Pereira, MD, FACS, Hospital de São Teotónio, Viseu, Portugal
- Principal Investigator: Amy Gillis, MD, MCh, FRCSC, Tallaght University Hospital, Dublin, Ireland
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- ESTESSnapshotAudit2018
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Cholangitis; Gallstone
-
University of British ColumbiaNot yet recruitingCalculi | Pathological Conditions, Anatomical | Cholecystitis, Acute | Gallbladder Diseases | Biliary Tract Diseases | Cholecystolithiasis | Choledocholithiasis | Digestive System Disease | Acute Cholangitis | Gallstone PancreatitisCanada
-
University Hospital, GenevaCompletedCholecystitis | Cholangitis | Choledocholithiasis | Gallstone Pancreatitis | Gallstone MigrationSwitzerland
-
PerspectumCompletedLiver Diseases | Primary Sclerosing Cholangitis | Gallstones | Primary Biliary CirrhosisUnited Kingdom
-
Lars Tue SorensenCopenhagen Trial Unit, Center for Clinical Intervention ResearchRecruitingPancreatitis | Cholangitis | Jaundice, Obstructive | Cholecystitis; GallstoneDenmark
-
Juan Carlos Martín del OlmoCompletedAcute Pancreatitis Due to Gallstones | Choledocholithiasis With Acute Cholangitis (Diagnosis)
-
University of ZurichUnknownSymptomatic Gallstone DiseaseSwitzerland
-
RenJi HospitalRecruitingPrimary Sclerosing Cholangitis | IgG4-related Sclerosing CholangitisChina
-
Brigham and Women's HospitalCompletedSclerosing CholangitisUnited States
-
HighTide Biopharma Pty LtdCompletedPrimary Sclerosing Cholangitis (PSC)United States, Canada
-
Intercept PharmaceuticalsCompletedPrimary Sclerosing Cholangitis (PSC)United States, Italy